胃癌患者在XELOX/SOX化疗期间身体组成的动态变化
Zhen-Hao Li1, Ting Xu2, Ya-Juan Zhang2
1The Clinical class 6 of First Clinical Medical College, Wenzhou Medical University, Wenzhou, China.
Frontiers in oncology
|May 15, 2024
概括
接受XELOX/SOX化疗的胃癌患者经历了显著的骨肌肉损失. 这种肌肉损耗与严重中性质衰竭的发病率较高相关,这是一个关键的副作用.
科学领域:
- 在瘤学瘤学.
- 营养科学 营养科学
- 身体组成分析 身体成分分析
背景情况:
- 胃癌治疗通常涉及化疗,这可能导致显著的生理变化.
- 了解化疗对身体组成的影响对于管理治疗毒性和患者结果至关重要.
研究的目的:
- 在胃癌患者的XELOX/SOX化疗期间评估身体组成的动态变化.
- 调查这些身体组成变化与严重中性质衰竭的发生之间的关联.
主要方法:
- 对接受XELOX/SOX化疗的39名胃癌患者的回顾性分析.
- 使用生物电阻分析和腰部3脊椎骨肌指数 (L3SMI) 评估身体组成.
- 使用常用术语对不良事件的标准评估中性质减退的严重程度 V.5.0.0.
主要成果:
- 在化疗后观察到,肉类症发病率显著增加 (46.2%至51.3%),平均L3SMI下降.
- 身体质量指数 (BMI),无脂肪质量指数 (FFMI),瘦体质量 (LBM) 和身体表面积 (BSA) 也显著下降.
- 在患有肉症的患者和在化疗期间骨肌指数下降的患者中,观察到≥3级中性衰竭的发病率较高.
结论:
- 在胃癌患者中,XELOX/SOX化学疗法导致骨肌肉逐渐枯竭.
- 骨肌肉质量的减少与严重中性质疏松症的风险增加有关,这凸显了营养监测和干预的重要性.
相关概念视频
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
197
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
197
Factors Influencing Drug Absorption: Disease States and Pharmacology
497
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
497
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159


